The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- Want to look better on your next Zoom call? Skin spa helps make sense of all the options out there – KPRC Click2Houston
- Two Pitt Faculty Members Inducted into National Academy of Medicine for Work on Aging and Neuro-Rehab – Newswise
- Franz Skincare USA Announces Second Consecutive Win of "Top Skincare Face Mask" in the 2020 Aesthetic Everything Aesthetic and Cosmetic…
- Dr. Kathryn Alcarez Joins The Exclusive Haute Beauty Network Representing The Medspa Category – PR Web
- Senior Horses and Living the Good Life The Horse – TheHorse.com
- Grab Pay Philippines
- GrabPay Philippines
- GrabPay Vietnam
- rajiv joshi ibm
- AI Trained on the Bible Spits Out Bleak Religious Prophecies
- hope frozem
- benchtop bioreactor market
- world economic forum how chemical industry boost stimulus
- are mushrooms the future of well ess
- Fururism this x ray map of the entire sky is
|Search Immortality Topics:|
Category Archives: Nano Medicine
Nanomedicine Market: Clear Understanding of The Competitive Landscape and Key Product Segments – PRnews Leader
Nanomedicineis an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 11,000 nm range, biochips, and polymer therapeutics.
Click Here to Get Sample Premium Report @https://www.trendsmarketresearch.com/report/sample/9807
Majority of nanomedicines prescribedcurrently, allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and bloodbrain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.
The Global Nanomedicine Market is estimated to witness a CAGR of 17.1% during the forecast period 20172023. The nanomedicine market is analyzed based on two segments therapeutic applications and regions.
The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.
The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.
Therapeutic Application Analysis:
Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.
Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.
At present, the nanomedicine market is at a nascent stage but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.
The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting – BioSpace
Oct. 20, 2020 06:00 UTC
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced four (4) clinical and/or pre-clinical presentations to be delivered at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting. Two presentations will be delivered by Nanobiotix and two will be delivered by the University of Texas MD Anderson Cancer Center.
Details of presentations:
Phase I Study of Intratumoral NBTXR3 in Combination with anti-PD-1 in Patients with Advanced Cancers Colette Shen, Jessica Frakes, Jiaxin Niu, Jared Weiss, Jimmy Caudell, Katherine Jameson, Patricia Said, Tanguy Seiwert
Abstract ID: 410
Date: Thursday, Nov. 12 from 4:505:20 p.m. EST and Saturday, Nov. 14 from 11:30 p.m. EST
Modulation of TCR Repertoire by Radiotherapy-activated NBTXR3 Nanoparticles Audrey Darmon, Ping Zhang, Sbastien Paris
Abstract ID: 582
Date: Thursday, Nov. 12 from 4:505:20 p.m. EST and Saturday, Nov. 14 from 11:30 p.m. EST
Overcoming Resistance to anti-PD-1 with Tumor Agnostic NBTXR3: From Bench to Bedside James W. Welsh, Colette Shen, Jessica Frakes, Jiaxin Niu, Jared Weiss, Jimmy Caudell, Hu Yun, Hampartsoum Barsoumian, Juliette Thariat, Sylvie Bonvalot, Zsusanna Papa; Maria Angelica Cortez, Ping Zhang, Katherine L. Jameson, Patricia Said, Sbastien Paris, Tanguy Seiwert,
Abstract ID: 396
Date: Thursday, Nov. 12 from 4:505:20 p.m. EST and Saturday, Nov. 14 from 11:30 p.m. EST
NBTXR3 Nanoparticle with Immunoradiation Improves Survival and Generates Long-term Anti-tumor Memory in an anti-PD1 Resistant Murine Lung Cancer Model Yun Hu, Sbastien Paris, Hampartsoum Barsoumian, Chike Osita Abana, Saumil Gandhi, Quynh-Nhu Nguyen, Maria Angelica Cortez, James W. Welsh
Abstract ID: 200
Date: Wednesday, Nov. 11 from 12:15 pm - 12:25 pm EST
NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response.
NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the Company has started the regulatory process to commence a phase III clinical trial in locally advanced head and neck cancers. In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.
Nanobiotix is also running an Immuno-Oncology development program. The Company has launched a Phase I clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1 therapy.
Other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and pancreatic cancer. The Company is also engaged in a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to further expand the NBTXR3 development program.
About NANOBIOTIX: http://www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotixs novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.
This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005776/en/
MagForce AG: ‘NanoTherm School’ successfully enters the third round with ‘Module B – Part II’ – PharmiWeb.com
DGAP-Media / 20.10.2020 / 09:50
MagForce AG: 'NanoTherm School' successfully enters the third round with 'Module B - Part II'
- MagForce successfully hosted the third session of the practice-oriented, unique and multifaceted application training series for the use of the NanoTherm therapy system for the treatment of glioblastoma.
- The NanoTherm School is part of MagForce's commitment to further optimize the therapy system and train healthcare professionals in its use, and to a broad geographic coverage to increase the availability of the therapy, in order to provide glioblastoma patients with the best care possible.
- The workshop was led by Univ.-Prof. Dr. med. W. Stummer, Director of the Department of Neurosurgery at the University Hospital Mnster
Berlin, October 20, 2020 - With 'Module B - Part II - stereotactic Instillation' MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, conducted the third round of its NanoTherm School.
The application training series was launched in January 2019 to provide the highest quality of treatment through ongoing support for physicians and certify surgeons in the use of the innovative NanoTherm technology. Same as the prior two sessions which took place in January and November 2019, Module B - Part II focused on advanced techniques in the area of stereotactic instillation and the teaching of the NanoPaste procedure.
Another focus was the exchange of information with the individual treatment centers to provide the best possible care for glioblastoma patients. NanoTherm School is part of MagForce's roll-out strategy, which focuses not only on broad geographical coverage to increase the availability of the therapy, but also on its continuous further optimization and the training of healthcare professionals in the use of the therapy system. The training concept of NanoTherm School was developed in close cooperation with Prof. Dr. Walter Stummer, Dr. Michael Schwake from the University Hospital Mnster and PD Dr. Johannes Wlfer from the Hufeland Klinikum GmbH Mhlhausen, who contribute their many years of experience with the NanoTherm therapy system for the treatment of glioblastoma patients.
Among the workshop participants were also representatives of new clinics that focus on the treatment of brain tumor patients, such as Dr. Georgios Naros, M.D., Senior Physician in the Department of Neurosurgery at the University Hospital of Tbingen and Prof. Dr. Angelika Gutenberg, Head of the Neurosurgery Section at Asklepios Klinikum Hamburg - her feedback: "Excellent, hands-on workshop from MagForce. Organization, motivation and high-end equipment cannot be improved!"
Senior Physician MUDr. Vilem Ruzicka, Paracelsus Klinik Zwickau said: "Thank you for a super organized certification course at the NanoTherm Therapy School of MagForce. It was a very successful and, above all, instructive workshop that provides us as medical practitioners with excellent training in the application of new technologies and therapies. This applies in particular to the very practical training of the various instillation methods and the subsequent evaluation of the results. The preparation and execution were very good, and overall it must be said that the set-up in the 'Medicine in the Green' is excellently suited for such workshops."
About NanoTherm School
Targeted towards medical professionals working in the fields of neuro-surgery and neuro-oncology, the 'NanoTherm Therapy School' series aims at introducing participants to the theoretical knowledge and practical techniques required to successfully apply MagForce's NanoTherm technology for the treatment of glioblastoma. In practicing their skills with human specimens, participants are able to familiarize themselves with the procedures and device usages in a stress-free environment under largely real operating conditions.
The 'NanoTherm School' is designed in three consecutive modules allowing participants to gain knowledge and understanding of MagForce's NanoTherm technology starting from basic application techniques (nanopasting) and building to advanced techniques and new surgical application forms in the final module (Module C). The practical section of the course is complemented by lectures on directly relevant aspects of NanoTherm therapy, as well as sample preparation and surgical videos. The equipment and facilities used during the course meet the requirements of today's state-of-the-art surgical equipment.
For more information about NanoTherm School, please contact:Dipl.-Ing. Tobias Hanitsch (email@example.com) Marcel Pilz (firstname.lastname@example.org)
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.
NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
For more information, please visit: http://www.magforce.com.Get to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.
Contact:Barbara von FrankenbergVice PresidentCommunications & Investor RelationsT +49-30-308380-77E-Mail: email@example.com
End of Media Release
20.10.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de
Healthcare Nanotechnology (Nanomedicine) Market: Analysis and In-depth Study on Healthcare Nanotechnology (Nanomedicine) Market Size Trends, Emerging…
The Healthcare Nanotechnology (Nanomedicine) market report offers a comprehensive and in-detail assessment of the Healthcare Nanotechnology (Nanomedicine) market and focuses on the key growth contributors of the market to gain a knowledgeable insight on the market. The report contains a detailed account of the history of the Healthcare Nanotechnology (Nanomedicine) market and a thorough and detailed forecast up to the year 2026.
The report takes into account the important factors and aspects that are crucial to the client to post good growth and establish themselves in the Healthcare Nanotechnology (Nanomedicine) market. Aspects such as sales, revenue, market size, mergers, acquisitions, risks, demands, new trends, threats, opportunities, and much more are taken into account to procure a detailed and descriptive research report on the Healthcare Nanotechnology (Nanomedicine) market.
Request Sample Report @ https://beathanreports.com/request-for-sample-report/36794
This report offers segmented data categorized as per related segments of the Healthcare Nanotechnology (Nanomedicine) market and as the international markets change, the report has documented all the essential aspects that affect the overall growth curve of the market. The reports cover all the segments extensively and offer a detailed explanation of all the factors crucial to growth.
The given report has been assessed to give maximum benefit to our clients and to establish them among the frontrunners in the Healthcare Nanotechnology (Nanomedicine) market. The report has been compiled by using various analyses that have proven to be a game-changer for many in the Healthcare Nanotechnology (Nanomedicine) market. The research sources and tools used by our analysts to assess the report are highly reliable and trustworthy and are approved by industry experts.
The following players are covered in this report:
Merck & Co
Johnson & Johnson
Kyowa Hakko Kirin
Request Discount About This Report @ https://beathanreports.com/discount-request-on-report/36794
The report offers effective guidelines and recommendations for players to secure a position of strength and dominance in the Healthcare Nanotechnology (Nanomedicine) market. The report offers extensive coverage of the competition and has a detailed account of the mergers, acquisitions in the Healthcare Nanotechnology (Nanomedicine) market landscape.
The report includes comprehensive data on mergers and acquisitions that will help the clients to get a complete idea of the market competition and also give you extensive knowledge on how to excel ahead and grow in the market.
Breakdown Data by Type
Nano Medical Devices
Healthcare Nanotechnology (Nanomedicine) Breakdown Data by Application
Based on regional and country-level analysis, the Healthcare Nanotechnology (Nanomedicine) market has been segmented as follows:
Rest of Europe
Rest of Asia-Pacific
Middle East & Africa
Rest of Middle East & Africa
Have Any Query ask to our Expert @ https://beathanreports.com/get-expert-help/36794
Reasons to buy:
WeissLaw LLP Reminds CPAA, TOTA, and LFAC Shareholders About Its Ongoing Investigations – PRNewswire
NEW YORK, Oct. 16, 2020 /PRNewswire/ --
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212)682-3025(888) 593-4771[emailprotected]
Conyers Park II Acquisition Corp. (NASDAQ: CPAA)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Conyers Park II Acquisition Corp. (NASDAQ: CPAA)in connection with the company's proposed merger with Advantage Solutions Inc. ("Advantage Solutions"), a privately-held sales and marketing company. Under the terms of the merger agreement, CPAA will acquire Advantage Solutions through a reverse merger that will result in Advantage Solutions becoming a public company listed company. The proposed transaction implies an initial enterprise value for Advantage Solutions of approximately $5.2 billion. If you own CPAA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/conyers-park-ii-acquisition-corp/
Tottenham Acquisition I Limited (NASDAQ: TOTA)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tottenham Acquisition I Limited (NASDAQ: TOTA, TOTAU, TOTAW, TOTAR)in connection with the company's proposed merger with privately-held clinical-stage biopharmaceutical company, Clene Nanomedicine, Inc. ("Clene"). Under the terms of the merger agreement, Tottenham will acquire Clene through a reverse merger that will result in Clene becoming a public company listed on the Nasdaq Capital Market. The proposed transaction values Clene at $542.5 million, and the new entity will receive $25 million from Tottenham's trust account. If you own TOTA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/tottenham-acquisition-i-limited/
LF Capital Acquisition Corp. (NASDAQ: LFAC)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of LF Capital Acquisition Corp. (NASDAQ: LFAC)in connection with the proposed acquisition of Landsea Homes Incorporated ("Landsea Homes"). Under the terms of the acquisition agreement, LFAC will acquire Landsea Homes through a reverse merger that will result in Landsea Homes becoming a publicly-listed company. The combined company is expected to have a pro forma equity value of approximately $510 million. Upon closing, Landsea Homes' founder, Landsea Green Properties Co., Ltd., will own 67.4% of the combined company. If you own LFAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/lf-capital-acquisition-corp/
SOURCE WeissLaw LLP
LOS GATOS, Calif.--(BUSINESS WIRE)--Advanced NanoTherapies, Inc., a privately-held medical device company committed to exploring nanotechnology for enhanced drug uptake and sustained retention, today announced it has closed on the final tranche of its seed-round financing for a total of $5.3 million as a result of achieving a successful pre-clinical milestone. Funding came from a variety of angel investment sources in the US, Canada, Europe, Asia, and the Middle East, including venture funding from Cleveland Clinic and ForMed Ventures of Taiwan.
Advanced NanoTherapies is led by CEO Marwan Berrada-Sounni, an entrepreneur with extensive experience in percutaneous therapies, including electrophysiology, structural heart, and cardiovascular and endovascular devices.
Our initial focus is on bringing a safer and more effective therapeutic option to patients with peripheral artery disease (PAD) using Sirolimus-coated angioplasty balloons, said Berrada-Sounni. This funding will help us accelerate the development process, build our infrastructure, and move towards bringing this novel technology to patients with PAD.
Advanced NanoTherapies technology platform leverages patented biodegradable functionalized nanoparticles (f-NPs) and a proprietary coating process developed at Cleveland Clinic.
We know that f-NPs enable and improve drug uptake and retention into cells and tissue, said inventor Vinod Labhasetwar, PhD., Professor and Endowed Chair of Nanomedicine, Department of Biomedical Engineering at Cleveland Clinic Lerner Research Institute. Due to technically challenging requirements involved in delivering Sirolimus efficiently to a stenosed artery, Advanced NanoTherapies use of f-NP is an innovative approach.
Advanced NanoTherapies licensed the technology from Cleveland Clinic Innovations.
While drug delivery using coated balloons is a well-established treatment strategy, our vision for using f-NP technology to address PAD represents a major advancement in drug-coated balloon (DCB) technology, said Dr. Mehdi Shishehbor, President, Harrington Heart and Vascular Institute University Hospitals, Cleveland and co-founder and Chief Medical Officer of Advanced NanoTherapies. This technology has implications for many other applications, such as coronary and peripheral in-stent restenosis, below-the-knee tibial disease in CLI, and dialysis AV graft treatment.
Berrada-Sounni added that the company will be working closely with the FDA to achieve an early feasibility study and introduce its technology to human populations.
About Advanced NanoTherapies
Co-founded by Marwan Berrada-Sounni, Advanced NanoTherapies, Inc. is a highly specialized medical device company that is developing a nanoparticle technology-based platform for drug delivery. The company is currently focused on cardiovascular and endovascular applications to bring a safer therapeutic option to patients with PAD using Sirolimus-coated angioplasty balloons. To learn more about Advanced NanoTherapies, visit http://www.AdvNanoT.com.
Go here to read the rest:
Advanced NanoTherapies Raises $5.3 Million in Seed-Round Financing - Business Wire